Given the chondrocytic origin shared by osteoarthritis (OA) and CHS, and the central role of PAR-2 in tumorigenic inflammation and matrix degradation, this mechanistic axis represents a promising therapeutic target in CHS. This evidence concerns the gene F2RL1 and osteoarthritis.